Skip to main content
Search
Home    /    Insights & Resources

Insights & Resources

Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.

For venture capital fund managers, understanding the Qualified Small Business Stock (QSBS) exemption presents a lucrative opportunity. Learn more in this overview.
FinCEN suspends Corporate Transparency Act reporting deadlines following order granting a preliminary injunction in federal district court in Texas.
Selecting an entity type in real estate is often decided by issues like tax flexibility. Here are some of the key considerations to keep in mind.
The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.
The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.
The initial enthusiasm for ESG in financial services was met with increased scrutiny, but the underlying ESG principles continue to hold sway.
Discover the key benefits and potential pitfalls of qualified small business stock (QSBS) in this essential guide for those navigating the QSBS landscape.
Join Becky Reeder and David Burch as they discuss 30 years of navigating the investment landscape and tactical strategies for emerging managers.
Discover how global manufacturers can navigate transfer pricing and foreign exchange volatility with Weaver’s Josh Finfrock and Bannockburn Global’s Greg Ciciola.
For many businesses, ASC 740 presents ongoing complexities as accounting for income taxes remains one of the most frequent drivers of restatements, control deficiencies and weaknesses due to a mixture of complex factors.
AI is revolutionizing industries, but misleading claims are rampant. Learn how the SEC combats AI washing and the importance of transparency for investment advisers.
Unravel life sciences industry complexities, and discover the differences between FDA special review designations like Fast Track, Priority Review and Breakthrough.
1 2 3 4 11